10 August 2025 - The already fraught oversight of rare disease treatments is becoming politicised.

To appreciate the dilemmas the FDA faces when it reviews new drugs targeting rare diseases, consider the recent rollercoaster ride of Sarepta Therapeutics, a biotech firm.

Read The Economist article